New York State Common Retirement Fund Buys 20,185 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

New York State Common Retirement Fund lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 98.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,657 shares of the company's stock after acquiring an additional 20,185 shares during the period. New York State Common Retirement Fund owned 0.06% of IDEAYA Biosciences worth $1,447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of IDYA. Federated Hermes Inc. raised its holdings in IDEAYA Biosciences by 14.8% during the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company's stock worth $138,185,000 after purchasing an additional 500,046 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of IDEAYA Biosciences during the 3rd quarter valued at about $2,265,000. Boone Capital Management LLC lifted its position in shares of IDEAYA Biosciences by 15.0% during the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company's stock worth $15,397,000 after purchasing an additional 74,249 shares in the last quarter. Barclays PLC increased its position in shares of IDEAYA Biosciences by 17.8% during the third quarter. Barclays PLC now owns 86,326 shares of the company's stock worth $2,330,000 after acquiring an additional 13,049 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in IDEAYA Biosciences in the third quarter valued at $9,038,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA traded up $0.53 on Friday, hitting $41.17. The stock had a trading volume of 446,904 shares, compared to its average volume of 825,619. The stock has a market cap of $3.08 billion, a P/E ratio of -20.04 and a beta of 0.83. The firm's fifty day simple moving average is $42.49 and its two-hundred day simple moving average is $38.42. IDEAYA Biosciences, Inc. has a 1 year low of $20.68 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. During the same quarter in the previous year, the firm earned ($0.49) earnings per share. IDEAYA Biosciences's revenue was down 100.0% compared to the same quarter last year. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDYA. Capital One Financial restated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Wedbush reissued an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday. Leerink Partnrs reiterated an "outperform" rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Citigroup lifted their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, March 21st. Finally, The Goldman Sachs Group lifted their price objective on IDEAYA Biosciences from $36.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, January 25th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of "Buy" and a consensus price target of $47.50.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.